Jose Canseco and Human Genetic Engineering
By Osagie Obasogie,
Cincinnati Enquirer
| 10. 21. 2005
Will He Be Right Again?
Recently, Jose Canseco and I were guests on a talk show to discuss gene doping, the genetic equivalent to anabolic steroids - a way to "juice up" to gain a competitive edge. It is possible that in the next few years athletes will be able to enhance their performance by altering their genetic make-ups. Canseco argued that gene doping "is definitely the next big step in evolution." Genetic enhancement, he said, "goes way beyond sports. Imagine an army of a million individuals who can out-think, out-use the environment in the sense of less food, more reaction time, better vision, better physical reaction . . . (T)he human race . . . is going to evolve and no one's gonna stop it."
It's easy to dismiss this as the ramblings of a B-list star struggling to keep himself in the limelight. Indeed, when Canseco released his now infamous "Juiced: Wild Times, Rampant 'Roids, Smash Hits, and How Baseball Got Big," this was most people's response. Yet we have been forced to swallow the bitter truthfulness of Canseco's pill. In the few...
Related Articles
By Emily Baumgaertner Nunn, The New York Times | 06.11.2026
When scientists at Columbia University announced they had used a newer technology to precisely edit the genes of human embryos last week, they set the academic community ablaze with debate. Is this good news or bad? How fast will...
By Ashley Smart , Undark | 06.24.2026
As Edward Donnell Ivy remembers it, many of the sickle cell episodes he endured in his 20s were akin to headaches or colds: They hurt, but he could still get up and go.
Every so often, though, he would be gripped...
By Samuelle Fajutrao Falk , The Conversation | 06.26.2026
When my colleagues and I asked autistic people and parents of autistic children in Sweden how they feel about genetic research in autism, one response stood out: “I hope genetic research finds new ways to help us, not erase us.”...
By Rebecca Simkin, BioNews | 06.29.2026
The US Food and Drug Administration (FDA) is allowing biotech company Regenxbio to reapply for licensing of a gene therapy for Hunter syndrome, in a reversal of its previous decision. Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is a...